Igc pharma names igc-ad1 phase 2 clinical trial for alzheimer's agitation "calma" and expands recruitment strategy

Innovative use of geofencing technology boosts enrollment at select sites potomac, md / accesswire / january 8, 2025 / igc pharma, inc. (nyse american:igc) ("igc pharma" or the "company") announced today that its ongoing phase 2 trial for agitation in alzheimer's disease has been officially named calma (calming agitation in alzheimer's). the trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
IGC Ratings Summary
IGC Quant Ranking